

## Endari<sup>™</sup> (L-glutamine) – New orphan drug approval

- On July 7, 2017, the <u>FDA announced</u> the approval of Emmaus Medical's <u>Endari (L-glutamine)</u>, to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients ≥ 5 years of age.
- SCD is an inherited blood disorder in which red blood cells (RBCs) are abnormally shaped as a crescent or "sickle". This restricts the flow in blood vessels, limits oxygen delivery to tissues, and may lead to severe pain and organ damage.
  - An estimated 100,000 Americans have SCD.
  - The average life expectancy for patients with SCD in the U.S. is approximately 40 to 60 years.
- Endari contains L-glutamine, an amino acid. While the mechanism of L-glutamine in treating SCD is not fully understood, it may increase the availability of reduced glutathione and lower the oxidative damage to RBCs.
- The safety and efficacy of Endari were based on a placebo-controlled trial in 230 patients 5 to 58 years of age with SCD who had two or more painful crises within the 12 months prior to trial enrollment. Efficacy was determined by a reduction in the number of sickle cell crises, defined as a visit to the emergency room/medical facility for SCD-related pain which was treated with a parenterally administered narcotic or parenterally administered <a href="ketorolac">ketorolac</a>. In addition, occurrence of chest syndrome, priapism, and splenic sequestration were considered sickle cell crises.
  - Patients treated with Endari vs. those treated with placebo experienced fewer sickle cell crises (median 3 vs. median 4), fewer hospitalizations for sickle cell pain (median 2 vs. median 3), and fewer days in the hospital (median 6.5 days vs. median 11 days).
  - Endari-treated patients also had fewer occurrences of acute chest syndrome vs. placebotreated patients (8.6% vs. 23.1%).
- The most common adverse reactions (> 10%) with Endari use were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain.
- The recommended dosage of Endari is administered orally twice daily based on body weight. See table below.

Weight (kg)	Weight (lbs)	Per dose	Per day	Packets/dose	Packets/day
< 30	< 66	5 gm	10 gm	1	2
30 – 65	66 – 143	10 gm	20 gm	2	4
> 65	> 143	15 gm	30 gm	3	6

- Each dose of Endari should be mixed before ingestion in 8 oz. (240 mL) of cold or room temperature beverage such as water, milk, or apple juice, or 4 oz. to 6 oz. of food such as applesauce or yogurt.
- Complete dissolution is not required prior to administration.
- Emmaus Medical's launch plans for Endari are pending. Endari will be available as an oral powder containing 5 gm of L-glutamine in paper-foil-plastic laminate packets.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.